At ViiV Healthcare our goal is clear: to end the HIV epidemic. We are focused on developing the next generation of HIV prevention and treatment options to meet the evolving needs of people living with HIV and those who benefit from PrEP.
Our pipeline reflects our “INSTI at the core” approach. We have a successful track record of developing and launching medicines centered on integrase strand transfer inhibitors (or integrase inhibitors or INSTIs) for the treatment and prevention of HIV. Our approach includes further developing INSTIs with a variety of other compounds – including broadly neutralising antibodies (bNAbs) or capsid inhibitors – into potential ultra long-acting therapies for treatment and prevention or long-acting injectables that could be self-administered.
We have a number of potential medicines in development for the treatment and prevention of HIV:
Clinical development pipeline
Compound number / Generic name / Brand name |
Indication |
Phase |
Mode of action / Vaccine type |
|---|---|---|---|
| VH3810109 ✝ | HIV |
Phase II |
HIV broadly neutralizing antibody |
| VH3739937 | HIV | Phase II | HIV maturation inhibitor |
| VH4011499 | HIV | Phase II | HIV capsid protein inhibitor |
| VH4524184 ✝ | HIV | Phase II | HIV integrase inhibitor |
| GSK1265744 cabotegravir |
HIV | Phase I | HIV integrase inhibitor |
✝In-license or other alliance relationship with third party
Pipeline progress
Our development pipeline changes over time as new projects progress from research to development. Our products in development progress through three stages: phase I, phase II, and phase III/registrational. Each phase allows us to assess the safety and efficacy of our products.
Compassionate use
Read more about our commitment to compassionate use within HIV clinical trials
.jpg?auto=format)
YOU MAY ALSO BE INTERESTED IN
An exciting and relatively new area of research in the development of next generation HIV treatments involves broadly neutralising antibodies (bNAbs).
The process of identifying, creating and developing generally well-tolerated and effective innovative HIV therapies is complex and requires ongoing collaboration between research teams that work in many different areas of medicines development.
We’ve got more than 50 active collaborations worldwide with pharmaceutical and biotechnology companies, government agencies, academic institutions and not-for-profit organisations to broaden our capabilities and enhance our performance.
NP-GBL-HVX-WCNT-230031 November 2024.
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.
